Mankind Pharma shares surged 4.5 percent on Monday, after the pharmaceutical company reported strong earnings growth for the second quarter of FY27. A sharp increase in net profit, double-digit revenue growth and an improvement in operating margins supported the rally.
Mankind Pharma stock closed at Rs 2,312, gaining 4.5 percent during the session. The stock has risen 6.8 percent so far in 2026, outperforming the Nifty 50, which has declined 13.1 percent over the same period. The company's market capitalisation stood at approximately Rs 95,500 crore.
Mankind Pharma reported a 39.2 percent year-on-year increase in net profit to Rs 712 crore for the quarter ended September 2026, compared with Rs 511.5 crore in the corresponding quarter last year. Revenue from operations rose 17.3 percent to Rs 4,338 crore from Rs 3,697.16 crore a year earlier, reflecting double-digit growth in the company's topline.
Share Markets Live Updates | Sensex, Nifty, GIFT Nifty Today
Domestic revenue increased 14.8 percent to Rs 3,657 crore, while exports jumped 32.7 percent to Rs 681 crore. The domestic pharmaceutical business, excluding consumer healthcare, registered 15.9 percent growth, supported by strong performance in chronic and acute therapies. The company reported growth of approximately 19 percent in cardiac therapies and 16 percent in anti-diabetes products, while its international business expanded 33 percent.